Kura Oncology KURA Commercialization Services — Revenue Remaining Performance Obligation
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
As of March 31, 2026, the remaining unrecognized consideration allocated to the development services for monotherapy was $27.0 million and to the development services in combination with other therapies was $161.7 million. As of March 31, 2026, $275.7 million of consideration allocated to commercialization services and profit and loss sharing payments received or expected to be received, was constrained and included in contract liabilities, of which $2.0 million was classified as current, and $273.7 million was classified as long-term.
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's commercialization services — revenue remaining performance obligation?
- Kura Oncology (KURA) reported commercialization services — revenue remaining performance obligation of $275.7M in Q1 2026.
- What does commercialization services — revenue remaining performance obligation mean?
- Represents the total transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. This metric provides visibility into the future revenue backlog expected to be recognized from commercialization service contracts. It is a key indicator of long-term revenue visibility and the health of the commercial pipeline.
Ask your AI about Kura Oncology's commercialization services — revenue remaining performance obligation.
Connect your AI assistant and compare segments, right in your chat.
